Tre (3%) af de 91 patienter i Vc+M+P- behandlingsgruppen, der fik profylatisk behandling med antivirale stoffer, udviklede herpes zoster- reaktivering.
31 of the 91 patients in the Vc+M+P treatment group who received prophylactic anti-virals developed herpes zoster reactivation.